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osting by EAbstract Many regions of the world, including Saudi Arabia, are medically vulnerable by the
spread of leishmaniasis. Although the effectiveness, the current available drugs suffer from the
appearance of resistant strains in epidemic areas and their toxic side-effects. We report the use of
the iron chelator deferoxamine (DFRX) that can be used as antileishmanial agents. Our experimen-
tal procedure was to follow up the growth of Leishmania major stages (extracellular promastigotes,
exinic extracellular amastigotes and intracellular amastigotes) in presence of the tested compound in
the culture media in different concentrations (10 lg/ml, 25 lg/ml, 50 lg/ml and no treatment) and
comparing it to the untreated control. The compound showed antileishmanial activities as it showed
great activity against the growth of the three Leishmania stages in a time and dose dependent man-
ner. Finally, this compound shows a promising potential activity to be a possible antileishmanial
compound alternatively or in combination with the currently used drugs.
ª 2010 King Saud University. All rights reserved.1. Introduction
Leishmaniasis is a parasitic protozoan disease that is caused by
obligate intra-macrophage parasite of genus Leishmania that is
transmitted by sandﬂies of genus Phlebotomus. It is endemic in
large areas of the tropics, subtropics and the Mediterranean
area (WHO, 2007). It consists of three main clinical forms:
cutaneous leishmaniasis (CL); muco-cutaneous leishmaniasisity. All rights reserved. Peer-
d University.
lsevier(MCL) and visceral leishmaniasis (VL). The species responsi-
ble for CL are mainly Leishmania major and Leishmania
tropica. Scars, psychological and social disgrace are the main
consequences of the CL. It is affecting approximately 12.5 mil-
lion people worldwide (WHO, 2007). Leishmania donovani and
Leishmania infantum are responsible for VL. It produces a life-
threatening disease with 500,000 new cases and around 50,000
deaths annually (WHO, 2007). It is lethal if left untreated
(Franc¸ois et al., 2007; Arevalo et al., 2007).
Leishmaniasis manifests a signiﬁcant health hazard in Saudi
Arabia. Cutaneous leishmaniasis (CL) occurs almost in all
parts of the country except the empty quarter. L. major and
L. tropica are the causative agents of CL in the country while
L. donovani and L. infantaum are responsible for VL (Peters
and Al-Zaharni, 1987; Ibrahim et al., 1994).
Only few drugs are available for the treatment of different
forms of leishmaniasis. Currently, it includes pentavalent
68 Saad M. Bin Dajemantimonials, amphotericin B and miltefosine. Pentavalent anti-
monials are of high cost and has severe side-effects (Melby,
2002). The development of resistance is of particular concern
(Sundar, 2001; Sundar et al., 2007). Amphotericin B has been
the alternative of antimonials as the ﬁrst-line treatment for VL
in some endemic areas (Berman, 2005). Milefosine has been
introduced as relatively safe and highly effective drug but it
has some side-effects (Bhattacharya et al., 2007). Due to these
problems associated with these drugs, researchers have utilized
many new compounds, inhibitors and drugs to overcome the
disadvantages appeared to the available leishmaniasis drugs.
Deferoxamine (DFRX), an iron chelator, and the similar
xenobiotics (e.g., cycloheximide, and pyrimethamine) have
been used as antiparasite drugs. Since it was introduced into
the market in 1960s, DFRX has been used as antiprotozoal
drug and its efﬁcacy has been investigated against several pro-
tozoan parasites. These include: Plasmodium spp. (Pradines
et al., 2006), Toxoplasma gondii, and Trypanosoma brucei
(Tanja et al., 2002). The efﬁcacy of DFRX has been investi-
gated against several protozoan parasites including Plasmo-
dium spp. (Pradines et al., 2006), T. gondii, and T. brucei
(Tanja et al., 2002). It exhibit moderate efﬁcacy against Babe-
sia (Matsuu et al., 2008). Also, it was used to treat Perkinsus
olseni the protozoan parasite of bivalve and showed in vitro
inhibition of the parasite proliferation (Laurence et al.,
2005). Desferrioxamine, a derivative of deferoxamine, was
used as liposome-entrapped compound and found to be
inactive against of promastigotes of L. donovani parasite
and showed a moderate efﬁcacy against amastigotes stages
(Segovia et al., 1989; Ketty et al., 1995).
Due to the problems associated with the drugs used against
Leishmania and the limited progress in developing a vaccine
against human leishmaniases, development of new chemother-
apeutic agents is highly required. No research has been done to
investigate the effect of this compound against L. major life
stages (extracellular promastigotes, exinic extracellular
amastigotes and intracellular amastigotes). In this study, we
tested deferoxamine (DFRX) for its effectiveness as antileish-
manial agents against the life cycle stages of L. major.
2. Materials and methods
2.1. Compounds and materials
All compounds and tissue culture chemicals used in this study
(RPMI, sodium bicarbonate, streptomycin, penicillin, etc.)
were mainly from Sigma Chemical Company (USA). Fetal calf
serum (FCS) was purchased from HyClone, USA.
2.2. Parasite
L. major isolate was provided by Dr. Ahmed Alkahtani, King
Fisal Specialist Hospital and research Center, Riyadh, Saudi
Arabia. It was isolated from a Saudi patient from Riyadh, Sau-
di Arabia. This study was approved by the Ethics Committee
at King Khalid University, Abha, Saudi Arabia.
2.3. Growth of Leishmania cells
Leishmania parasite was maintained in the laboratory in
RPMI containing 10% fetal calf serum (FCS). Amastigoteswere obtained by incubating promastigotes in RPMI supple-
mented with 10% FCS and the pH of the media was adjusted
to pH 5. Cells were incubated at 37 C in 5% CO2.
2.4. Growth and experimental infection of J774A.1 macrophages
in vitro
J774A.1 macrophage cell line was maintained in RPMI-1640
medium with 10% FCS. Tissue culture ﬂasks containing mac-
rophages were placed in a CO2 incubator (5% CO2) at 37 C.
The experiment was started by optimizing in vitro infection of
macrophage with Leishmania promastigotes. Macrophages
were inoculated with L. major in a 10:1 ratio (promastigote:
macrophage) and the infection was monitored microscopically.
2.5. Drug administration to axenic amastigotes and
promastigotes
Drug administration to both stages was carried out according to
Al-Qahtani et al. (2009). Brieﬂy, Parasites were grown in 24-well
plates and seeded at 5 · 106 parasite/ml of culturemedia.DFRX
was dissolved in a dimethylsulfoxide (DMSO) and added to the
wells in triplicate in a ﬁnal concentration of 10 lg/ml, 25 lg/ml
or 50 lg/ml. The drug was added at day 1 and every 48 h. Con-
trol cells were treated with DMSO (0.4% ﬁnal concentration)
andwere always included in all experiment. The cell counts were
recorded using a Neubauer haemocytometer.2.6. Drug administration to infected macrophages
Macrophages (106 cells) were growing in Lab-Tek Perma-
nox Chamber Slide (Electron Microscopy Sciences, Hatﬁeld,
PA, USA). Stationary phase promastigotes were added to
each well in 10:1 ratio (promastigotes:macrophages) to each
well. DFRX was added at different concentrations (10 lg/
ml, 25 lg/ml or 50 lg/ml) to each well and the plates were
incubated at 37 C. Triplicate incubations in the presence or
absence of DFRX were maintained in all experiments.
DFRX has been used in concentrations that have been previ-
ously shown to be non-toxic to mammalian cells (Crichton
and Ward, 1992). The drug was added at day 1 and then
every 48 h during the course of the experiment. The cells
and the intracellular amastigotes were counted directly under
the microscope.
2.7. Statistical analysis
Differences in growth of the parasite in all experiments (treated
with DFRX versus untreated control cells) were analyzed
using one-way ANOVA test using SPSS software (version
11; SPSS Inc., Chicago, Illinois, USA). All p values <0.05
were considered signiﬁcant.3. Results
3.1. In vitro infection of macrophage by L. major
The in vitro infection of macrophage by Leishmania was mon-
itored microscopically. It was found that promastigotes were
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In vitro evaluation of the efﬁcacy of deferoxamine against Leishmania major life cycle stages 69phagocytozed by macrophages, differentiated into amastigotes
and multiplied within the host cells.
3.2. Effect of iron chelators on growth of Leishmania
Treatment Leishmania promastigotes with (DFXM) causes
growth inhibition during the investigated intervals compared
to non-treated cells. In Table 1, ANOVA analysis among differ-
ent concentrations showed very high signiﬁcant changes
(p< 0.001) while the least signiﬁcant differences test showed
very highly signiﬁcant decrease (p< 0.001) when 10 lg/ml
was administered compared with 25 lg/ml and 50 lg/ml of
(DFXM) was used. When axenically-grown amastigotes were
incubated in the presence of (DFXM), multiplication of
amastigotes was halted compared to vehicle-treated parasites.
ANOVAanalysis between different concentrations showed very
high signiﬁcant changes (p< 0.001) while the least signiﬁcant
differences test showed very highly signiﬁcant decrease
(p< 0.001) especially with 50 lg/ml dose (Table 1). To investi-
gate the role of iron chelator on multiplication of Leishmania
amastigoteswithin J774.1macrophages, therewas a great reduc-
tion in the number of intracellular parasites within host cells. Ta-
ble 2 showed that ANOVA analysis between different
concentrations were of very high signiﬁcant changes
(p< 0.001) while the least signiﬁcant differences test showed
very highly signiﬁcant decrease especially with 50 lg/ml
(Table 2).4. Discussion
Owing to the worldwide distribution of leishmaniasis and the
problems associated with the current drugs, development of
new chemotherapeutic agents is essential. The success of the
parasite to survive in the mammalian host depends largely
on its ability to invade macrophages and to transform to
amastigotes, the stage that is adopted to live in the tissue of
the mammalian host (Bogdan et al., 1996). The organic penta-
valent antimoniates, which are the clinical drugs most fre-
quently employed against leishmaniasis, have been in use for
several decades. However, antimoniates have been associated
with considerable toxicity to humans. The spread of drug-resis-
tant Leishmania strains in several endemic areas stresses the ur-
gent need of identifying new chemotherapeutic means against
leishmaniasis. Amphotericin B and miltefosine have been also
used. Each of the above mentioned drugs has its own limita-
tions (toxicity, price, efﬁcacy and treatment schedules) (Santos
et al., 2008; Davis and Kedzierski, 2005).
Iron is a required nutritional substance that is essential for
eukaryotic cell growth and differentiation (Crichton andWard,
1992). Pathogenic agents are dependent on iron for their growth,
it has been postulated that iron-chelating compounds may be
effective in eliminating or reducing infection. The discovery of
transferrin receptor on Leishmania parasite suggests that sufﬁ-
cient availability of iron is essential for the life cycle (Ketty
et al., 1995). In this study, deferoxamine showed great efﬁcacy
against L. major different stages. It has been also shown that
the depletion of Iron results in impairment of DNA synthesis
(Crichton and Ward, 1992) When treated with iron-chelating
agent, It is assumed that pathogens inhibition is caused by inac-
tivation of ribonucleotide reductase (RBRD), an iron-depen-
dent rate-limiting enzyme in DNA synthesis (Hoffbrand et al.
Table 2 The effect of in different doses of Deferoxamine on the number of intracellular amastigotes.
Dose Period
0 day 3 days 6 days 9 days 12 days 15 days 18 days 21 days 24 days
No treatment 0.0 ± 0.0 18 ± 0.6 21 ± 0.6 30 ± 0.6 35 ± 0.6 38 ± 0.6 47 ± 0.6 46 ± 0.6 46 ± 0.6
25 lg/ml 0.0 ± 0.0 18 ± 0.6 21 ± 0.6 16 ± 0.6*** 26 ± 0.6*** 31 ± 0.6*** 35 ± 0.6*** 35 ± 0.6*** 32 ± 0.6***
50 lg/ml 0.0 ± 0.0 19 ± 0.6 18 ± 0.6*** 18 ± 0.6*** 20 ± 0.6*** 23 ± 0.6*** 15 ± 0.6*** 15 ± 0.6*** 15 ± 0.6***
All values are mean ± SE.
*p< 0.05, **p< 0.01, ***p< 0.001 in comparison with non-treated group.
70 Saad M. Bin Dajem1976; JordanandReichard, 1998). It seems reasonable to assume
that same parameters could be applicable in both promastigotes
and amastigotes of Leishmania. RBRD has identiﬁed in Leish-
mania with properties similar to that of its mammalian counter-
part. However, inhibition of growth of intracellular amastigotes
shown in this study may be due to several factors. In addition to
the effects of iron chelatormentioned above, removal of iron has
been shown to induce secretion of cytokines and to induce apop-
tosis in several cell lines. Both mechanisms could lead to reduc-
tion of growth of intracellular amastigotes. Lastly, one of the
interesting ﬁndings of this research is the indirect evidence that
Leishmania amastigotes possess RBRD activity since growth
of these parasites was inhibited in the presence of DFXM. It
has been also shown that both Leishmania amastigotes and
promastigotes contain sizable quantities of iron stored in an
organelle known as acidocalcisome (Al-Qahtani, 1990). Taken
together, it is not surprising to ﬁnd that iron depletion is detri-
mental to extracellular or intracellular growth of Leishmania.
This compound has been used as antiparasitic drug. When
DFXM used againstT. brucei, it has been found that it inhibits
the proliferation of the parasites and was postulated that the ef-
fect of this compound on the activity of alternative oxidase of
blood stages forms lower the rate of DNA synthesis (Cooper
et al., 1996). In vitro and in vivo studies with Trypanosomacruzi,
Plasmodium falciparum, Plasmodium vinckei, and Plasmodium
berghei in mice, rats and monkeys have all shown that this com-
pound has the ability to inhibit the proliferation of these para-
sites. (Lalonde and Holbein, 1986; Fritsch etal., 1985; Gordeuk
et al., 1993; Hershko and Peto, 1988; Pollack et al., 1987; Pra-
dines et al., 2006) When used as antiparasite against Babesia
gibsoni in vitro it exhibited intermediate effectiveness (Matsuu
et al., 2008). In a study of bivalve clam parasite, P. olseni, it
has been shown that, this iron chelator failed to eliminate light
infections in the clam despite their in vitro antiprotozoal prop-
erties (Laurence et al., 2005). The present study suggested that
iron depletion may be an effective against Leishmania infection.
However, usage of iron chelators as a possible antileishmanial
therapy must be taken with great care since they could create
potential health disorders for host as has been noted with other
infectious agents (Golenser et al., 2003)
In conclusion, the tested drug has shown to possess a prom-
ising antileishmanial activity in vitro system. Furthermore,
their effect in vivo in experimental animals should be per-
formed to draw a meaningful conclusion.Acknowledgements
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